In a turbulent market, experts recommend five stocks with strong technical indicators for short-term investments. From ...

The drugmaker posted a profit of Rs 1,298 crore in the quarter-ended June, according to an exchange filing on Friday.

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Stock Market Today: The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Dolat Capital upgrade its FY26E/FY27E EPS estimates of Cipla by 1.2%/2.1%, assuming higher US sales than earlier, hence ...

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas ...

Cipla, the country’s third-largest drugmaker by market value, was the top gainer on the Nifty 50 on Friday, rising over 3 per ...

With the stock showing a rise of 2.09%, Cipla continues to be a key player in the pharmaceutical sector, demonstrating steady financial performance and active corporate actions.

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla stock surges over 5% in two days, surpassing key resistance, potential for further gains. Watch bl.Today’s Pick.